Acurx Pharmaceuticals (ACXP) investor relations material

Executive summary

• FDA provided conditional acceptance for a single phase III trial (IBZ-ASPIRE) as pivotal for NDA filing, with further discussion at a pre-NDA meeting after completion of IBZ-ASPIRE and other supporting trials.

• Focused on developing a novel class of antibiotics targeting serious bacterial infections, with lead candidate ibezapolstat showing strong Phase 2 results for C. difficile infection (CDI).

• PATHFINDER study in recurrent CDI is fully funded and expected to start enrollment in Q4 2026; results will support regulatory filings.

• Proprietary name Syfbezi for ibezapolstat received FDA conditional acceptance and USPTO trademark allowance.

• Scientific partnerships and preclinical data support the advancement of DNA Pol IIIC inhibitors for resistant gram-positive infections.

Financial highlights

• Cash at quarter-end was $10.7 million, up from $7.6 million at year-end 2025; working capital stood at $8.2 million.

• Raised $2.5 million via registered direct offering and $0.8 million from equity line of credit during the quarter.

• R&D expenses for Q2 2026 were $1.1 million, up 104% year-over-year, mainly due to manufacturing and consulting costs for new trials.

• General and administrative expenses for Q2 2026 were $1.2 million, down 29% year-over-year.

• Net loss for Q2 2026 was $2.3 million ($0.53/share), compared to $2.2 million ($1.89/share) in Q2 2025.

Outlook and guidance

• IBZ-ASPIRE phase III trial will be international, targeting countries with high CDI incidence; screening has not yet begun.

• Management expects continued net losses and negative cash flows for the foreseeable future; current cash resources are not sufficient for at least 12 months, requiring additional financing.

• PATHFINDER trial is fully funded and will provide key data for regulatory and partnership discussions.

• Ongoing efforts to secure additional funding for the ASPIRE trial and broader commercialization.

• Received FDA and EMA agreement on Phase 3 trial design for ibezapolstat, providing a clear regulatory path for US and EU submissions.